Sirolimus for Kaposi's Sarcoma in Renal-Transplant Recipients
Top Cited Papers
Open Access
- 31 March 2005
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 352 (13) , 1317-1323
- https://doi.org/10.1056/nejmoa042831
Abstract
Recipients of organ transplants are susceptible to Kaposi's sarcoma as a result of treatment with immunosuppressive drugs. Sirolimus (rapamycin), an immunosuppressive drug, may also have antitumor effects.Keywords
This publication has 23 references indexed in Scilit:
- Akt plays a central role in sarcomagenesis induced by Kaposi's sarcoma herpesvirus-encoded G protein-coupled receptorProceedings of the National Academy of Sciences, 2004
- Rapamycin is an effective inhibitor of human renal cancer metastasis11See Editorial by Sukhatme and Strom, p. 1160.Kidney International, 2003
- Initiation of angiogenic Kaposi's sarcoma lesionsCancer Cell, 2003
- Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factorNature Medicine, 2002
- Vascular Endothelial Growth Factor-C Stimulates the Migration and Proliferation of Kaposi's Sarcoma CellsJournal of Biological Chemistry, 1999
- Cyclosporine induces cancer progression by a cell-autonomous mechanismNature, 1999
- Vascular endothelial growth factor/vascular permeability factor is an autocrine growth factor for AIDS–Kaposi sarcomaProceedings of the National Academy of Sciences, 1997
- RENAL TRANSPLANTATION EXPOSES PATIENTS WITH PREVIOUS KAPOSI'S SARCOMA TO A HIGH RISK OF RECURRENCE1Transplantation, 1996
- Mechanism of action of rapamycin: New insights into the regulation of G1-phase progression in eukaryotic cellsPublished by Springer Nature ,1995
- Identification of Herpesvirus-Like DNA Sequences in AIDS-Sssociated Kaposi's SarcomaScience, 1994